Physicians' Academy for Cardiovascular Education

Implications from SHARP

3' education - July 21, 2011

Protecting the heart and the kidney: Implications from the SHARP trial

During a recently held PACE Master Class Lipid Innovations, Professor Jane Armitage (Clinical Trials Service Unit, University of Oxford, United Kingdom) presented the results of the Study of Heart and Renal Protection (SHARP).  Professor John Betteridge (University College London, United Kingdom) discussed the implications from this trial with her during a video interview.

Questions to be addressed in this PACE expert opinion are:

  • The SHARP trial in patients with advanced renal disease: What are the main findings and how do they advance our knowledge on LDL lowering?
  • With respect to major atherosclerotic events: Where there any differences by renal status?
  • SHARP study medication: Why did you use simvastatin and ezetimibe in SHARP?
  • When targeting LDL lowering: Do you think these results are encouraging for treating this patient group?

View prof Betteridge in discussion with prof Armitage

About the speakers

Prof. D John Betteridge,
Consultant Physician, University College London Hospitals, London, UK, Emeritus Professor of Endocrinology and Metabolism University College London, and Associate Dean Royal Society of Medicine.

Prof Jane Armitage,
Professor of Clinical Trials and Epidemiology and Honorary Consultant in Public Health Medicine at the University of Oxford, United Kingdom


View the Powerpoint slides presented

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: